Skip to content

Research Areas

Biosfer Teslab has more than 90 publications in multiple research areas. 

Abnormal lipid metabolism is associated with gestational diabetes mellitus (GDM) and is observed in neonates with abnormal fetal growth. However, the underlying …

Background: Limited studies have evaluated the joint influence of redox-related metals and genetic variation on metabolic pathways. We analyzed the association of …

Background: The contribution of metabolomic factors to the association of healthy lifestyle with type 2 diabetes risk is unknown. We assessed the association …

High plasma triglyceride (TG) levels and chronic inflammation are important factors related to metabolic-associated fatty liver disease in patients at cardiovascular risk. …

Abstract High plasma triglyceride (TG) levels and chronic inflammation are important factors related to metabolic-associated fatty liver disease in patients at cardiovascular …

Patients with type 2 diabetes mellitus (T2DM) and atherogenic dyslipidemia (AD) are at higher risk of developing cardiovascular diseases (CVDs), so an …

We aimed to assess the potential relationship between dietary patterns (i.e., Mediterranean diet and healthy eating) and the advanced lipoprotein profile (ALP) …

Aims: The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined. …

Introducción y objetivos El fenotipado avanzado de lipoproteínas es mejor predictor del riesgo aterosclerótico que el colesterol. El perfil de lipoproteínas en …

Introduction and objectives: Advanced lipoprotein phenotyping is a better predictor of atherosclerotic cardiovascular risk than cholesterol concentration alone. Lipoprotein profiling in heart failure …

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020